Alembic gets USFDA nod for infection treatment drug

Alembic Pharmaceuticals has received final approval from the USFDA for its abbreviated new drug application (ANDA) Azithromycin Tablets USP, 600 mg

318
Approved approval nod
Picture: Pixabay
< 1 min. read

New Delhi : Drug firm Alembic Pharmaceuticals said it has received a final nod from the US health regulator for Azithromycin tablets, used for the treatment of infections.

“Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Azithromycin Tablets USP, 600 mg,” the drug firm said in a filing to BSE.

Azithromycin tablet is a macrolide antibacterial drug indicated for mild to moderate infections.

The approved ANDA is therapeutically equivalent to the reference listed drug product Zithromax tablets, 600 mg, of Pfizer, the filing said.

Also read: Alembic Pharma gets US FDA approval for generic Tracleer tablets

Citing IQVIA, the company said Azithromycin tablets USP, 600 mg have an estimated market size of USD 2 million for 12 months ending September 2019.

Alembic Pharmaceuticals has a cumulative total of 115 ANDA approvals (103 final approvals and 12 tentative approvals) from USFDA.

The shares of the company were trading at Rs 628.35 a piece on BSE in morning trade, up 2.20 per cent from the previous close.

LEAVE A REPLY

Please enter your comment!
Please enter your name here